We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-3.45%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$334M
AUM Growth
-$21.5M
Cap. Flow
+$1.64M
Cap. Flow %
0.49%
Top 10 Hldgs %
52.03%
Holding
83
New
4
Increased
23
Reduced
12
Closed
11
Avg Time Held
10.3 quarters
Top 10 Avg Time Held
6.4 quarters
Top 20 Avg Time Held
8 quarters

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$3.77M
2
IPSC icon
Century Therapeutics
IPSC
+$3.65M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.89M
4
PRQR icon
ProQR Therapeutics
PRQR
+$2.88M
5
RVMD icon
Revolution Medicines
RVMD
+$2.41M

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$5.56M
2
ETNB icon
89bio
ETNB
+$4.13M
3
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$3.65M
4
BHVN icon
Biohaven
BHVN
+$2.51M
5
VKTX icon
Viking Therapeutics
VKTX
+$2.09M

Sector Composition

Rank Sector Weight
1 Healthcare 83.01%
2 Miscellaneous 16.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$43.4M 13.02%
570,000
+4,000
+0.7% +$332K
2022 Q1
4 quarters
STXS icon
2
Stereotaxis
STXS
$106M
$27.9M 8.37%
13,680,554
– –
2013 Q2
39 quarters
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$14.9M 4.47%
612,975
+7,000
+1% +$153K
2020 Q2
11 quarters
ASND icon
4
Ascendis Pharma A/S
ASND
$14.7B
$14.5M 4.35%
135,212
+5,000
+4% +$572K
2021 Q4
5 quarters
KRTX icon
5
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$14.3M 4.28%
78,573
+6,546
+9% +$1.25M
2020 Q1
12 quarters
IBB icon
6
iShares Biotechnology ETF
IBB
$10.2B
$13.2M 3.97%
102,500
– –
2016 Q4
25 quarters
RVMD icon
7
Revolution Medicines
RVMD
$40.4B
$12.5M 3.74%
575,785
+98,000
+21% +$2.41M
2020 Q4
9 quarters
BPMC icon
8
DELISTED
Blueprint Medicines
BPMC
$11.8M 3.52%
261,235
– –
2016 Q4
25 quarters
XENE icon
9
Xenon Pharmaceuticals
XENE
$3.33B
$11.3M 3.39%
316,092
– –
2015 Q3
30 quarters
CYTK icon
10
Cytokinetics
CYTK
$8.57B
$9.73M 2.92%
276,495
+92,500
+50% +$3.77M
2021 Q3
6 quarters
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.25B
$9.44M 2.83%
447,073
– –
2020 Q2
11 quarters
DXCM icon
12
DexCom
DXCM
$32.1B
$7.85M 2.35%
67,552
– –
2017 Q3
22 quarters
SAGE icon
13
DELISTED
Sage Therapeutics
SAGE
$7.57M 2.27%
180,306
– –
2017 Q4
21 quarters
NBIX icon
14
Neurocrine Biosciences
NBIX
$13.7B
$7.55M 2.26%
74,615
+1,494
+2% +$155K
2016 Q1
28 quarters
MORF icon
15
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$6.76M 2.03%
179,467
-16,000
-8% -$590K
2020 Q4
9 quarters
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.31B
$6.43M 1.93%
468,358
– –
2020 Q3
10 quarters
CSII
17
DELISTED
Cardiovascular Systems, Inc.
CSII
$5.7M 1.71%
286,988
– –
2018 Q2
19 quarters
DICE icon
18
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$5.37M 1.61%
187,585
+64,085
+52% +$1.9M
2022 Q1
4 quarters
VKTX icon
19
Viking Therapeutics
VKTX
$3.39B
$5.31M 1.59%
319,155
-202,398
-39% -$2.09M
2018 Q4
17 quarters
MRUS icon
20
DELISTED
Merus
MRUS
$5.23M 1.57%
283,998
+14,105
+5% +$246K
2021 Q1
8 quarters
ATRC icon
21
AtriCure
ATRC
$2.89B
$5.2M 1.56%
125,529
+53,500
+74% +$2.22M
2013 Q2
39 quarters
NRIX icon
22
Nurix Therapeutics
NRIX
$2.42B
$5.03M 1.51%
566,695
– –
2021 Q1
8 quarters
EWTX icon
23
Edgewise Therapeutics
EWTX
$3.94B
$4.89M 1.47%
733,239
-33,604
-4% -$311K
2022 Q1
4 quarters
KALV icon
24
DELISTED
KalVista Pharmaceuticals
KALV
$4.84M 1.45%
616,032
– –
2021 Q1
8 quarters
BCRX icon
25
BioCryst Pharmaceuticals
BCRX
$2.06B
$4.6M 1.38%
551,500
+300,500
+120% +$2.89M
2022 Q4
1 quarter
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, DAFNA Capital Management held 83 positions worth $334M, down 6.1% from $355M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2023 filing shows 4 new, 23 increased, 12 reduced and 11 closed positions. Its largest new stake was ProQR Therapeutics: 940,582 shares worth $2M. The largest sale was Fate Therapeutics, an estimated $5.56M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 83% a quarter earlier, followed by Miscellaneous.

  • DAFNA Capital Management's largest Q1 2023 buy was ProQR Therapeutics: 940,582 shares worth $2M.
  • DAFNA Capital Management added most to Cytokinetics in Q1 2023, an estimated $3.77M increase.
  • DAFNA Capital Management's biggest Q1 2023 reduction was Biohaven, cutting an estimated $2.51M.
  • DAFNA Capital Management fully exited Fate Therapeutics in Q1 2023, selling an estimated $5.56M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $334M portfolio in Q1 2023.
  • DAFNA Capital Management opened 4 new positions and closed 11 in Q1 2023.
  • DAFNA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $334M.

Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.